Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients (original) (raw)

Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation

Janel Boyle

Pharmaceutics

View PDFchevron_right

Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning

Janel Boyle

Translational Research, 2016

View PDFchevron_right

Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer

Peter Steinherz

Cancer Chemotherapy and Pharmacology, 2011

View PDFchevron_right

Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes

M. Bierings

Blood Advances, 2019

View PDFchevron_right

Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC–MS/MS

Janel Boyle

Journal of Pharmaceutical and Biomedical Analysis, 2013

View PDFchevron_right

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial

Claire Dearden

Cancer, 2010

View PDFchevron_right

Outcomes of Substituting Oral Fludarabine for Intravenous Fludarabine in Combination with Cytarabine and Filgrastim for Treatment of Primary Refractory or Relapsed Acute Leukemias

Roberta Demichelis-gómez

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 2015

View PDFchevron_right

Fludarabine in chronic leukaemia

Alan Astrow

The Lancet, 1996

View PDFchevron_right

Fludarabine Allows Dose Reduction for Total Body Irradiation in Pediatric Hematopoietic Stem Cell Transplantation

Shiao Woo

International Journal of Radiation Oncology*Biology*Physics, 2007

View PDFchevron_right

Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes

Leslie Shaw

Bone Marrow Transplantation, 2010

View PDFchevron_right

Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration

Giuseppe G M Leone, Dimitar Efremov

Annals of Hematology, 2008

View PDFchevron_right

Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS

Janel Boyle

Journal of Chromatography B, 2014

View PDFchevron_right

Pharmacokinetic targeting of iv BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve …

leonard perez

Bone Marrow …, 2010

View PDFchevron_right

Fludarabine and Exposure-Targeted Busulfan Compares Favorably with Busulfan/Cyclophosphamide-Based Regimens in Pediatric Hematopoietic Cell Transplantation: Maintaining Efficacy with Less Toxicity

birgitta versluys

Biology of Blood and Marrow Transplantation, 2014

View PDFchevron_right

Determination of fludarabine in a pharmaceutical formulation by LC

Antonino Villari

Journal of Pharmaceutical and Biomedical Analysis, 1999

View PDFchevron_right

Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia

B. Cazin

Haematologica, 2013

View PDFchevron_right

The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia

Eric Haarman

International Journal of Oncology, 2004

View PDFchevron_right

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen

Julio Delgado

Cytotherapy, 2009

View PDFchevron_right

In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine

Paula Fernández Calotti

Biochemical Pharmacology, 2003

View PDFchevron_right

Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia

Anna Candoni

…, 1998

View PDFchevron_right

Population pharmacokinetics and optimal design of paediatric studies for famciclovir

Kayode Ogungbenro

British Journal of Clinical Pharmacology, 2009

View PDFchevron_right

Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias

Mary Rios

Clinical cancer research : an official journal of the American Association for Cancer Research, 2003

View PDFchevron_right

Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome

Pat Chiusolo

Annals of Hematology, 2010

View PDFchevron_right

Fludarabine phosphate for the treatment of low grade lymphoid malignancy

Owen Smith

British Journal of Cancer, 1991

View PDFchevron_right

Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6

Abebe Haregewoin

The Oncologist, 2012

View PDFchevron_right

Use of clofarabine for acute childhood leukemia

Andrea Pession

Biologics: Targets & Therapy, 2010

View PDFchevron_right

Effect of Fludarabine on Leukocyte Functions

ayça doğan

Chemotherapy, 2004

View PDFchevron_right

Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors

Jerry Guy

Investigational New Drugs, 1991

View PDFchevron_right

Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

Judith Karp

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017

View PDFchevron_right

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics

Andrew McLachlan

Frontiers in Pharmacology

View PDFchevron_right